Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trialJonathan E. Rosenberg, Robert Dreicer, Jean Hoffman‐Censits et al.|The Lancet|2016Cited by 3.7k
Pembrolizumab as Second-Line Therapy for Advanced Urothelial CarcinomaJoaquim Bellmunt, Dean F. Bajorin, Ronald de Wit et al.|New England Journal of Medicine|2017Cited by 3.4k
MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancerThomas Powles, Nicholas J. Vogelzang, Yohann Loriot et al.|Nature|2014Cited by 2.4k
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trialArjun Vasant Balar, Dean F. Bajorin, Matthew D. Galsky et al.|The Lancet|2016Cited by 2.2k
Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial CarcinomaThomas Powles, Petros Grivas, Se Hoon Park et al.|New England Journal of Medicine|2020Cited by 1.5k